New Delhi, Jan. 30 -- Piramal Pharma Ltd, which has a strong presence in the inhaled anaesthetic generics segment in the US and emerging markets, plans to expand its pipeline of injectables to drive growth, chairperson Nandini Piramal told Mint in an interview.

The company launched Chlorpromazine Hydrochloride, an injectable used to treat psychiatric disorders, in the US on 22 January. This is the latest injectable from Piramal Critical Care, the company's complex hospital generics arm.

In 2024, it launched Edaravone injection, used to treat amyotrophic lateral sclerosis (ALS), and a new concentration of Zinc Sulfate for injection, which followed the Pantoprazole Sodium injectable and the Doxycycline injectable in 2023.

"There will be ...